Nosocomial Infections in HIV-Positive Patients: An Overview

Infection, Supplement

Volumn 31, Issue 2, 2003, Pages 28-34

  Petrosillo, N ^a   Pagani, L ^b   Ippolito, G ^a   Viale, P ^c  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b General Hospital of Bolzano   (Italy)

^c UNIVERSITY OF UDINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL COLONIZATION; BLOODBORNE BACTERIUM; CONFERENCE PAPER; GASTROINTESTINAL INFECTION; HOSPITAL ADMISSION; HOSPITAL INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE DEFICIENCY; INCIDENCE; INTRAVASCULAR CATHETER; LITERATURE; PATIENT CARE; PHYSICIAN; RESPIRATORY TRACT INFECTION; REVIEW; URINARY TRACT INFECTION; VIRUS INFECTION;

BACTEREMIA; CATHETERIZATION; CROSS INFECTION; DIARRHEA; HIV INFECTIONS; HUMANS; INFECTION CONTROL; PROSPECTIVE STUDIES; RESPIRATORY TRACT INFECTIONS; RISK FACTORS;

EID: 0442291998     PISSN: 01732129     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (98)

1. Craven DE, Steger KA, Hirschhorn LR: Nosocomial colonization and infection in persons infected with human immunodeficiency virus. Infect Control Hosp Epidemiol 1996; 17:304-18.
2. Boumis E, Petrosillo N, Girardi E, De Carli G, Armignacco O, Visca P, Ippolito G: Changing patterns in the etiology of HIV-associated bacterial pneumonia in the era of highly active antiretroviral therapy. Eur J Clin Microbiol Infect Dis 2001; 20:71-3.
3. Paul S, Gilbert HM, Lande L, Vaamonde CM, Jacobs J, Malak S, Sepkowitz KA: Impact of antiretroviral therapy on decreasing hospitalization rates of HIV-infected patients in 2001. AIDS Res Hum Retroviruses 2002; 18:501-6.
4. Martin-Carbonero L, Soriano V, Valencia E, Garcia-Samaniego J, Lopez M, Gonzalez-Lahoz J: Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses 2001; 17:1467-71.
5. Soriano V, Martin-Carbonero L, Garcia-Samaniego J, Puoti M: Mortality due to chronic viral liver disease among patients infected with human immunodeficiency virus. Clin Infect Dis 2001; 33:1793-5.
6. Goetz AM, Squier C, Wagener MM, Muder RR: Nosocomial infections in the human immunodeficiency virus-infected patient: a two-year survey. Am J Infect Control 1994; 22:334-9.
7. Weber DJ, Becherer PR, Rutala WA, Samsa GP, Wilson MB, White GC, 2nd: Nosocomial infection rate as a function of human immunodeficiency virus type 1 status in hemophiliacs. Am J Med 1991; 91:206S-212S.
8. Stroud L, Srivastava P, Culver D, Bisno A, Rimland D, Simberkoff M, Elder H, Fierer J, Martone W, Gaynes R: Nosocomial infections in HIV-infected patients: preliminary results from a multicenter surveillance system (1989-1995). Infect Control Hosp Epidemiol 1997; 18:479-85.
9. National Nosocomial Infections Surveillance System (NNISS): Semi-annual report, December 1999. Atlanta: NNISS, 1999.
10. Petrosillo N, Pugliese G, Girardi E, Pallavicini F, Carosi G, Moro ML, Ippolito G: Nosocomial infections in HIV infected patients. Gruppo HIV e Infezioni Ospedaliere. AIDS 1999; 13:599-605.
11. Frank U, Daschner FD, Schulgen G, Mills J: Incidence and epidemiology of nosocomial infections in patients infected with human immunodeficiency virus. Clin Infect Dis 1997; 25:318-20.
12. Petrosillo N, Viale P, Nicastri E, Arici C, Bombana E, Casella A, Cristini F, De Gennaro M, Dodi F, Gabbuti A, Gattuso G, Irato L, Maggi P, Pallavicini F, Pan A, Pantaleoni M, Ippolito G: Nosocomial bloodstream infections among human immunodeficiency virus-infected patients: incidence and risk factors. Clin Infect Dis 2002; 34:677-85.
13. Lambotte O, Lucet JC, Fleury L, Joly-Guillou ML, Bouvet E: Nosocomial bacteremia in HIV patients: the role of peripheral venous catheters. Infect Control Hosp Epidemiol 2000; 21:330-3.
14. Meyer CN, Skinhoj P, Prag J: Bacteremia in HIV-positive and AIDS patients: incidence, species distribution, risk-factors, outcome, and influence of long-term prophylactic antibiotic treatment. Scand J Infect Dis 1994; 26:635-42.
15. Nystrom B, Larsen SO, Dankert J, Daschner F, Greco D, Gronroos P, Jepsen OB, Lystad A, Meers PD, Rotter M: Bacteraemia in surgical patients with intravenous devices: a European multicentre incidence study. The European Working Party on Control of Hospital Infections. J Hosp Infect 1983; 4:338-49.
16. Nicastri E, Petrosillo N, Viale P, Ippolito G: Catheter-related bloodstream infections in HIV-infected patients. Ann N Y Acad Sci 2001; 946:274-90.
17. Astagneau P, Maugat S, Tran-Minh T, Douard MC, Longuet P, Maslo C, Patte R, Macrez A, Brucker G: Long-term central venous catheter infection in HIV-infected and cancer patients: a multicenter cohort study. Infect Control Hosp Epidemiol 1999; 20:494-8.
18. Groeger JS, Lucas AB, Thaler HT, Friedlander-Klar H, Brown AE, Kiehn TE, Armstrong D: Infectious morbidity associated with long-term use of venous access devices in patients with cancer. Ann Intern Med 1993; 119:1168-74.
19. Thorne JE, Jabs DA, Vitale S, Miller T, Dunn JP, Semba RD: Catheter complications in AIDS patients treated for cytomegalovirus retinitis. AIDS 1998; 12:2321-7.
20. Skiest DJ, Grant P, Keiser P: Nontunneled central venous catheters in patients with AIDS are associated with a low infection rate. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17:220-6.
21. Mokrzycki MH, Schroppel B, von Gersdorff G, Rush H, Zdunek MP, Feingold R: Tunneled-cuffed catheter associated infections in hemodialysis patients who are seropositive for the human immunodeficiency virus. J Am Soc Nephrol 2000; 11:2122-7.
22. Moro ML, Vigano EF, Cozzi Lepri A: Risk factors for central venous catheter-related infections in surgical and intensive care units. The Central Venous Catheter-Related Infections Study Group. Infect Control Hosp Epidemiol 1994; 15:253-64.
23. Stanley HD, Charlebois E, Harb G, Jacobson MA: Central venous catheter infections in AIDS patients receiving treatment for cytomegalovirus disease. J Acquir Immune Defic Syndr 1994; 7:272-8.
24. Van der Pijl H, Frissen PH: Experience with a totally implantable venous access device (Port-A-Cath) in patients with AIDS. AIDS 1992; 6:709-13.
25. Moore DA, Gazzard BG, Nelson MR: Central venous line infections in AIDS. J Infect 1997; 34:35-40.
26. Goodman HE, Brettle RP, Stevenson B, Hamilton B, Kalima P, Leen CL: Central venous catheter in patients with AIDS. Int J STD AIDS 1999; 8:417-22.
27. Domingo P, Fontanet A, Sanchez F, Allende L, Vazquez G: Morbidity associated with long-term use of totally implantable ports in patients with AIDS. Clin Infect Dis 1999; 29:346-51.
28. Viale P, Politi E, Sisti M, Confalonieri M, Alberici F: Impact of central venous catheters (CVC) management on infectious risk. J Hosp Infect 1998; 40:P.8.1.8
29. Warren DK, Zack JE, Elward AM, Cox MJ, Fraser VJ: Nosocomial primary bloodstream infections in intensive care unit patients in a non-teaching community medical center: a 21-month prospective study. Clin Infect Dis 2001; 33:1329-35.
30. Simon A, Fleischhack G, Hasan C, Bode U, Engelhart S, Kramer MH: Surveillance for nosocomial and central line-related infections among pediatric hematology-oncology patients. Infect Control Hosp Epidemiol 2000; 21:592-6.
31. Senthilkumar A, Kumar S, Sheagren JN: Increased incidence of Staphylococcus aureus bacteremia in hospitalized patients with acquired immunodeficiency syndrome. Clin Infect Dis 2001; 33:1412-6.
32. Pedro-Botet L, Modol JM, Valles X, Romeu J, Sopena N, Gimenez ML, Tor J, Clotet B, Sabria M: Changes in bloodstream infections in HIV-positive patients in a university hospital in Spain (1995-1997). Int J Infect Dis 2002; 6:17-22.
33. Nguyen MH, Kauffman CA, Goodman RP, Squier C, Arbeit RD, Singh N, Wagener MM, Yu VL: Nasal carriage of and infection with Staphylococcus aureus in HIV-infected patients. Ann Intern Med 1999; 130:221-5.
34. von Eiff C, Becker K, Machka K, Stammer H, Peters G: Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med 2001; 344:11-6.
35. Koziol-Montewka M, Chudnicka A, Ksiazek A, Majdan M: Rate of Staphylococcus aureus nasal carriage in immunocompromised patients receiving haemodialysis treatment. Int J Antimicrob Agents 2001; 18:193-6.
36. Sissolak D, Geusau A, Heinze G, Witte W, Rotter ML: Risk factors for nasal carriage of Staphylococcus aureus in infectious disease patients, including patients infected with HIV, and molecular typing of colonizing strains. Eur J Clin Microbiol Infect Dis 2002; 21:88-96.
37. Amir M, Paul J, Batchelor B, Kariuki S, Ojoo J, Waiyaki P, Gilks C: Nasopharyngeal carriage of Staphylococcus aureus and carriage of tetracycline-resistant strains associated with HIV-seropositivity. Eur J Clin Microbiol Infect Dis 1995; 14:34-40.
38. Battan R, Raviglione MC, Wallace J, Cort S, Boyle JF, Taranta A: S. aureus nasal carriage among homosexual men with and without HIV infection. Am J Infect Control 1991; 19:98-100.
39. Shapiro M, Smith KJ, James WD, Giblin WJ, Margolis DJ, Foglia AN, McGinley K, Leyden JJ: Cutaneous microenvironment of human immunodeficiency virus (HIV)-seropositive and HIV-seronegative individuals, with special reference to Staphylococcus aureus colonization. J Clin Microbiol 2000; 38:3174-8.
40. Holbrook KA, Klein RS, Hartel D, Elliott DA, Barsky TB, Rothschild LH, Lowy FD: Staphylococcus aureus nasal colonization in HIV-seropositive and HIV-seronegative drug users. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:301-6.
41. Kluytmans J, van Belkum A, Verbrugh H: Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 1997; 10:505-20.
42. Onorato M, Borucki MJ, Baillargeon G, Paar DP, Freeman DH, Cole CP, Mayhall CG: Risk factors for colonization or infection due to methicillin-resistant Staphylococcus aureus in HIV-positive patients: a retrospective case-control study. Infect Control Hosp Epidemiol 1999; 20:26-30.
43. Groux H, Torpier G, Monte D, Mouton Y, Capron A, Ameisen JC: Activation-induced death by apoptosis in CD4+ T cells from human immunodeficiency virus-infected asymptomatic individuals. J Exp Med 1992; 175:331-40.
44. Wininger DA, Fass RJ: Impact of trimethoprim-sulfamethoxazole prophylaxis on etiology and susceptibilities of pathogens causing human immunodeficiency virus-associated bacteremia. Antimicrob Agents Chemother 2002; 46:594-7.
45. Laing RB: Nosocomial infections in patients with HIV disease. J Hosp Infect 1999; 43:179-85.
46. Hirschtick RE, Glassroth J, Jordan MC, Wilcosky TC, Wallace JM, Kvale PA, Markowitz N, Rosen MJ, Mangura BT, Hopewell PC: Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group. N Engl J Med 1995; 333:845-51.
47. Wallace JM, Hansen NI, Lavange L, Glassroth J, Browdy BL, Rosen MJ, Kvale PA, Mangura BT, Reichman LB, Hopewell PC: Respiratory disease trends in the pulmonary complications of HIV infection study cohort. Pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care Med 1997; 155:72-80.
48. Viale P, Scudeller L, Signorini L, Cadeo B, Petrosillo N, Pagani L, POP-HIV-Stdy Group: HIV-associated community-acquired pneumonia in the HAART era. AIDS 2002; 16:2361-2.
49. Afessa B, Green B: Clinical course, prognostic factors, and outcome prediction for HIV patients in the ICU. The PIP (Pulmonary complications, ICU support, and prognostic factors in hospitalized patients with HIV) Study. Chest 2000; 118:138-45.
50. Afessa B, Green B: Bacterial pneumonia in hospitalized patients with HIV infection: the Pulmonary Complications, ICU Support, and Prognostic Factors of Hospitalized Patients with HIV (PIP) Study. Chest 2000; 117:1017-22.
51. Tumbarello M, Tacconelli E, de Gaetano Donati K, Bertagnolio S, Cataldo M, Pirronti T, Ardito F, Cauda R: Nosocomial bacterial pneumonia in human immunodeficiency virus infected subjects: incidence, risk factors and outcome. Eur Respir J 2001; 17:636-40.
52. Baril L, Astagneau P, Nguyen J, Similowski T, Mengual X, Beigelman C, Caumes E, Katlama C, Bricaire F: Pyogenic bacterial pneumonia in human immunodeficiency virus-infected inpatients: a clinical, radiological, microbiological, and epidemiological study. Clin Infect Dis 1998; 26:964-71.
53. Redd SC, Rutherford GW, 3rd, Sande MA, Lifson AR, Hadley WK, Facklam RR, Spika JS: The role of human immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents. J Infect Dis 1990; 162:1012-7.
54. Manfredi R, Nanetti A, Ferri M, Chiodo F: Pseudomonas spp. complications in patients with HIV disease: an eight-year clinical and microbiological survey. Eur J Epidemiol 2000; 16:111-8.
55. Sorvillo F, Beall G, Turner PA, Beer VL, Kovacs AA, Kerndt PR: Incidence and determinants of Pseudomonas aeruginosa infection among persons with HIV: association with hospital exposure. Am J Infect Control 2001; 29:79-84.
56. Meynard JL, Barbut F, Guiguet M, Batisse D, Lalande V, Lesage D, Guiard-Schmid JB, Petit JC, Frottier J, Meyohas MC: Pseudomonas aeruginosa infection in human immunodeficiency virus infected patients. J Infect 1999; 38:176-81.
57. Bouza SE, Blazquez GR, Rodriguez-Creixems M, Moreno GS, Miralles MP, Alonso FR: Bacteremia caused by P. aeruginosa in patients with AIDS. Rev Clin Esp 1996; 196
58. Takeoka K, Ichimiya T, Yamasaki T, Nasu M: The in vitro effect of macrolides on the interaction of human polymorphonuclear leukocytes with Pseudomonas aeruginosa in biofilm. Chemotherapy 1998; 44:190-7.
59. Molinari G, Guzman CA, Pesce A, Schito GC: Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics. J Antimicrob Chemother 1993; 31:681-8.
60. Nicolau DP, Banevicius MA, Nightingale CH, Quintiliani R: Beneficial effect of adjunctive azithromycin in treatment of mucoid Pseudomonas aeruginosa pneumonia in the murine model. Antimicrob Agents Chemother 1999; 43:3033-5.
61. Viale P, Petrosillo N, Castelli F, Cadeo B, Carosi G: Algorithm-based management of pneumonia in HIV-1-infected patients. Lancet 2002; 359:359-60.
62. Antonucci G, Girardi E, Raviglione MC, Ippolito G: Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. The Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA). JAMA 1995; 274:143-8.
63. Ozbay B, Uzun K: Extrapulmonary tuberculosis in high prevalence of tuberculosis and low prevalence of HIV. Clin Chest Med 2002; 23:351-4.
64. Moro ML, Errante I, Infuso A, Sodano L, Gori A, Orcese CA, Salamina G, D'Amico C, Besozzi G, Caggese L: Effectiveness of infection control measures in controlling a nosocomial outbreak of multidrug-resistant tuberculosis among HIV patients in Italy. Int J Tuberc Lung Dis 2000; 4:61-8.
65. Djuretic T, Herbert J, Drobniewski F, Yates M, Smith EG, Magee JG, Williams R, Flanagan P, Watt B, Rayner A, Crowe M, Chadwick MV, Middleton AM, Watson JM: Antibiotic resistant tuberculosis in the United Kingdom: 1993-1999. Thorax 2002; 57:477-82.
66. Sacks LV, Pendle S, Orlovic D, Blumberg L, Constantinou C: A comparison of outbreak- and non-outbreak related multidrug-resistant tuberculosis among human immunodeficiency virus-infected patients in a South African hospital. Clin Infect Dis 1999; 29:96-101.
67. Cobo J, Asensio A, Moreno S, Navas E, Pintado V, Oliva J, Gomez-Mampaso E, Guerrero A: Risk factors for nosocomial transmission of multidrug-resistant tuberculosis due to Mycobacterium bovis among HIV-infected patients. Int J Tuberc Lung Dis 2001; 5:413-8.
68. Hannan MM, Peres H, Maltez F, Hayward AC, Machado J, Morgado A, Proenca R, Nelson MR, Bico J, Young DB, Gazzard BS: Investigation and control of a large outbreak of multidrug-resistant tuberculosis at a central Lisbon hospital. J Hosp Infect 2001; 47:91-7.
69. Tuberculosis outbreaks in prison housing units for HIV-infected inmates-California, 1995-1996. MMWR Morb Mortal Wkly Rep 1999; 48:79-82.
70. Drug-susceptible tuberculosis outbreak in a state correctional facility housing HIV-infected inmates - South Carolina, 1999-2000. MMWR Morb Mortal Wkly Rep 2000; 49:1041-4.
71. Conover C, Ridzon R, Valway S, Schoenstadt L, McAuley J, Onorato I, Paul W: Outbreak of multidrug-resistant tuberculosis at a methadone treatment program. Int J Tuberc Lung Dis 2001; 5:59-64.
72. Di Perri G, Cruciani M, Danzi MC, Luzzati R, De Checchi G, Malena M, Pizzighella S, Mazzi R, Solbiati M, Concia E: Nosocomial epidemic of active tuberculosis among HIV-infected patients. Lancet 1989; 2:1502-4.
73. Girardi E, Raviglione MC, Antonucci G, Godfrey-Faussett P, Ippolito G: Impact of the HIV epidemic on the spread of other diseases: the case of tuberculosis. AIDS 2000; 14:S47-56.
74. Cruciani M, Malena M, Bosco O, Gatti G, Serpelloni G: The Impact of human immunodeficiency virus type 1 on infectiousness of tuberculosis: a meta-analysis. Clin Infect Dis 2001; 33:1922-30.
75. Menzies D, Fanning A, Yuan L, Fitzgerald M: Tuberculosis among health care workers. N Engl J Med 1995; 332:92-8.
76. Di Perri G, Cadeo GP, Castelli F, Micciolo R, Bassetti S, Rubini F, Cazzadori A, Marocco S, Carlotto A, Adami T, et al: Transmission of HIV-associated tuberculosis to healthcare workers. Infect Control Hosp Epidemiol 1993; 14:67-72.
77. Ridzon R, Kenyon T, Luskin-Hawk R, Schultz C, Valway S, Onorato IM: Nosocomial transmission of human immunodeficiency virus and subsequent transmission of multidrug-resistant tuberculosis in a healthcare worker. Infect Control Hosp Epidemiol 1997; 18:422-3.
78. Bennett CL, Schwartz DN, Parada JP, Sipler AM, Chmiel JS, De-Hovitz JA, Goetz MB, Weinstein RA: Delays in tuberculosis isolation and suspicion among persons hospitalized with HIV-related pneumonia. Chest 2000; 117:110-6.
79. Kovacs JA, Gill VJ, Meshnick S, Masur H: New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia. JAMA 2001; 286:2450-60.
80. Dumoulin A, Mazars E, Seguy N, Gargallo-Viola D, Vargas S, Cailliez JC, Aliouat EM, Wakefield AE, Dei-Cas E: Transmission of Pneumocystis carinii disease from immunocompetent contacts of infected hosts to susceptible hosts. Eur J Clin Microbiol Infect Dis 2000; 19:671-8.
81. Miller RF, Ambrose HE, Wakefield AE: Pneumocystis carinii f. sp. hominis DNA in immunocompetent health care workers in contact with patients with P. carinii pneumonia. J Clin Microbiol 2001 Nov; 39(11):3877-82.
82. Hennequin C, Page B, Roux P, Legendre C, Kreis H: Outbreak of Pneumocystis carinii pneumonia in a renal transplant unit. Eur J Clin Microbiol Infect Dis 1995; 14:122-6.
83. Cheung YF, Chan CF, Lee CW, Lau YL: An outbreak of Pneumocystis carinii pneumonia in children with malignancy. J Paediatr Child Health 1994; 30:173-5.
84. Santiago-Delpin EA, Mora E, Gonzalez ZA, Morales-Otero LA, Bermudez R: Factors in an outbreak of Pneumocystis carinii in a transplant unit. Transplant Proc 1988; 20:S462-5.
85. Olsson M, Eriksson BM, Elvin K, Strandberg M, Wahlgren M: Genotypes of clustered cases of Pneumocystis carinii pneumonia. Scand J Infect Dis 2001; 33:285-9.
86. Duse AG: Nosocomial infections in HIV-infected/AIDS patients. J Hosp Infect 1999; 43:S191-201.
87. Manfredi R, Calza L, Chiodo F: Enteric and disseminated Campylobacter species infection during HIV disease: a persisting but significantly modified association in the HAART era. Am J Gastroenterol 2002; 97:510-1.
88. Paton S, Nicolle L, Mwongera M, Kabiru P, Mirza N, Plummer F, Wamola I: Salmonella and Shigella gastroenteritis at a public teaching hospital in Nairobi, Kenya. Infect Control Hosp Epidemiol 1991; 12:710-7.
89. Hutin Y, Molina JM, Casin I, Daix V, Sednaoui P, Welker Y, Lagrange P, Decazes JM, Modai J: Risk factors for Clostridium difficile-associated diarrhoea in HIV-infected patients. AIDS 1993; 7:1441-7.
90. Tumbarello M, Tacconelli E, Leone F, Cauda R, Ortona L: Clostridium difficile-associated diarrhoea in patients with human immunodeficiency virus infection: a case-control study. Eur J Gastroenterol Hepatol 1995; 7:259-63.
91. Barbut F, Mario N, Meyohas MC, Binet D, Frottier J, Petit JC: Investigation of a nosocomial outbreak of Clostridium difficile-associated diarrhoea among AIDS patients by random amplified polymorphic DNA (RAPD) assay. J Hosp Infect 1994; 26:181-9.
92. Tacconelli E, Tumbarello M, de Gaetano Donati K, Leone F, Mazzella P, Cauda R: Clostridium difficile-associated diarrhea in human immunodeficiency virus infection - a changing scenario. Clin Infect Dis 1999; 28:936-7.
93. Brites C, Weyll M, Pedroso C, Badaro R: Severe and Norwegian scabies are strongly associated with retroviral (HIV-1/HTLV-1) infection in Bahia, Brazil. AIDS 2002; 16:1292-3.
94. Sirera G, Rius F, Romeu J, Llibre J, Ribera M, Soriano V, Tor J, Ferrandiz C, Clotet B: Hospital outbreak of scabies stemming from two AIDS patients with Norwegian scabies. Lancet 1990; 335:1227.
95. Corbett EL, Crossley I, Holton J, Levell N, Miller R, De Cock KM: Crusted ("Norwegian") scabies in a specialist HIV unit: successful use of ivermectin and failure to prevent nosocomial transmission. Genitourin Med 1996; 72:115-7.
96. Guggisberg D, de Viragh PA, Constantin C, Panizzon RG: Norwegian scabies in a patient with acquired immunodeficiency syndrome. Dermatology 1998; 197:306-8.
97. Meinking TL, Taplin D, Hermida JL, Pardo R, Kerdel FA: The treatment of scabies with ivermectin. N Engl J Med 1995 6; 333:26-30.
98. Alberici F, Pagani L, Ratti G, Viale P: Ivermectin alone or in combination with benzyl benzoate in the treatment of human immunodeficiency virus-associated scabies. Br J Dermatol 2000; 142:969-72.